Journal of the American Academy of Dermatology
July 9, 2026 · via Europe PMC
Real-world outcomes of 24-week abrocitinib tapering in moderate-to-severe atopic dermatitis: Feasibility and regimen comparison.
Deng S, He Y, Wang H, Chen Q, Gao C, Song Z.
AI summary — for doctors, generated from the abstract only
In well-responding atopic dermatitis patients, 24-week abrocitinib tapering succeeded in 97%, with dose reduction more stable than interval extension.
What was studied
Single-centre retrospective study of 78 patients with moderate-to-severe AD tapered over 24 weeks by dose reduction (36) or interval extension (42).
Key findings
- Successful tapering in 97.4%
- Non-relapse 97.4% at week 12 and 91.0% at week 24
- Cumulative dose reduced by 9,892 mg with cost savings
- Strategy switching more common with interval extension (28.6% vs 8.3%, P=0.041)
Clinical relevance
This suggests abrocitinib tapering is feasible in good responders, with dose reduction possibly preferable, but data are retrospective with short follow-up.
Who should care
Limitations
Single-centre retrospective design, small sample, short follow-up.
Abrocitinib can often be tapered in well-controlled AD, preferably by lowering the dose.
This is an AI-generated summary of the published abstract, not a clinical recommendation. It may not reflect the full text or subsequent updates — verify against the original source before acting on it.
Abstract
Background
Evidence regarding the feasibility of Janus kinase inhibitors tapering following adequate response in moderate-to-severe atopic dermatitis (AD) remains limited, and no head-to-head comparisons of tapering regimens have been conducted.
Objective
To evaluate the feasibility of 24-week abrocitinib tapering in moderate-to-severe AD patients having achieved adequate response and compare 2 tapering methods.
Methods
This retrospective study enrolled moderate-to-severe AD patients who achieved adequate clinical response with abrocitinib and underwent tapering over 24 weeks via dose reduction or interval extension.
Results
A total of 78 patients (36 dose reduction, 42 interval extension) were included, and successful tapering was achieved in 76 (97.4%). Nonrelapse rates were 97.4% and 91.0% at weeks 12 and 24, respectively. At week 24, mean cumulative dose was reduced by 9892 mg (6908 mg vs 16,800 mg standard), with cost savings of ¥ 2899.5 (¥ 2016.7 vs ¥ 4916.2 projected). Patients with extended dosing intervals had significantly higher strategy-switch rates due to disease fluctuation [28.6% (12/42) vs 8.3% (3/36), P = .041].
Limitations
The single-center retrospective design, small sample size, and relatively short follow-up duration.
Conclusion
Twenty-four-week abrocitinib tapering appears feasible in well-responding moderate-to-severe AD patients, reducing treatment burden while preserving efficacy.
DOI
10.1016/j.jaad.2026.06.064
PMID
42423580
Research metadata (titles, abstracts, authors, publication dates) is sourced from Europe PMC, which aggregates content from PubMed/MEDLINE, PubMed Central, and other providers under the U.S. National Library of Medicine (NLM/NCBI). NLM does not claim copyright on abstracts; the original journal publishers or authors may hold rights to the full articles. AI-generated summaries are derived only from the abstract, never the full text, and are always labeled as AI-generated.
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
Back to the research feed